NEW YORK (GenomeWeb News) — The Ontario Genomics Institute has appointed as new directors Alastair Glass, Jay Lefton and Tim McTiernan.
Glass is deputy minister of Ontario’s Ministry of Research and Innovation. He has served as director of information and communications technology at the Science Foundation of Ireland and spent 30 years at Bell Laboratories and served as chief technical officer at Lucent Technologies.
Lefton is a senior partner at the Toronto-based law firm Aird & Berlis and has served on the Ontario Securities Commission’s advisory committee and on the board at the University of Toronto’s Rotman School of Business.
McTiernan is the executive director of innovations and assistant vice president of research at the University of Toronto. He is a founding president of BIOLink Canada-Ireland and is former president of Canadore College of Applied Arts Technology.
Biomarker diagnostics developer Singulex has added Andre Marion to its board of directors, the company said this week.
Marion is the founder of Applied Biosystems. He is currently a director at Molecular Devices, Applied Imaging, Alpha M.O.S., and Guava Technologies.
He was CEO at ABI for seven years and was chairman of the board for six, after which he served as vice president at PerkinElmer.
Alpha Innotech has hired Jeff Whitmore to be the new vice president of the company’s global sales department.
Whitmore was recently director of European life science sales for Molecular Devices. Before that he was involved in US sales at Molecular Devices and at BioRad Laboratories.
Metabolon, a metabolomics biomarker development company, said this week it has named Christopher Macri director of business development. Macri formerly was a director of business development at GeneLogic.
National Heart, Lung and Blood Institute Director Elizabeth Nabel has received the 2006 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition. The coalition grants the award to recognize contributions in science, business or in policy that advances the field of personalized medicine.
Nabel has previously served as director of Cardiovascular Research Center at the University of Michigan.